{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:52:24Z","timestamp":1791064344010,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"DOI":"10.1007\/s15010-026-02968-8","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:02:44Z","timestamp":1791018164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated analysis of HIV-1 drug resistance across reverse transcriptase, protease and integrase in india: gene-region-corrected prevalence and threshold-specific scoring from public sequence data"],"prefix":"10.1007","author":[{"given":"Amlan","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoomika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfeena","family":"Topiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanshi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5959-024X","authenticated-orcid":false,"given":"Vijay","family":"Kevlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2968_CR1","volume-title":"India HIV Estimates 2023: Technical Report","author":"Organisation NAC, Statistics I-NIoM","year":"2024","unstructured":"Organisation NAC, Statistics I-NIoM. India HIV Estimates 2023: Technical Report. New Delhi: Ministry of Health and Family Welfare, Government of India; 2024."},{"key":"2968_CR2","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016."},{"key":"2968_CR3","volume-title":"Status of National AIDS and STD Response","author":"NAC Organisation","year":"2023","unstructured":"Organisation NAC, Sankalak. Status of National AIDS and STD Response. 5th ed. New Delhi: Ministry of Health and Family Welfare, Government of India; 2023.","edition":"5"},{"key":"2968_CR4","volume-title":"National guidelines for HIV care and treatment, 2021","author":"National Aids Control Organisation","year":"2021","unstructured":"National Aids Control Organisation. National guidelines for HIV care and treatment, 2021. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India; 2021."},{"issue":"10","key":"2968_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350(10):1023\u201335. https:\/\/doi.org\/10.1056\/NEJMra025195.","journal-title":"N Engl J Med"},{"issue":"6","key":"2968_CR6","doi-asserted-by":"publisher","first-page":"e39819","DOI":"10.1371\/journal.pone.0039819","volume":"7","author":"U Neogi","year":"2012","unstructured":"Neogi U, Bontell I, Shet A, De Costa A, Gupta S, Diwan V, et al. Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. PLoS ONE. 2012;7(6):e39819. https:\/\/doi.org\/10.1371\/journal.pone.0039819.","journal-title":"PLoS ONE"},{"issue":"10","key":"2968_CR7","doi-asserted-by":"publisher","first-page":"ofac481","DOI":"10.1093\/ofid\/ofac481","volume":"9","author":"SJ Clipman","year":"2022","unstructured":"Clipman SJ, Solomon SS, Srikrishnan AK, McFall AM, Gomathi S, Saravanan S, et al. Antiretroviral drug resistance in HIV sequences from people who inject drugs and men who have sex with men across 21 cities in India. Open Forum Infect Dis. 2022;9(10):ofac481. https:\/\/doi.org\/10.1093\/ofid\/ofac481.","journal-title":"Open forum Infect Dis"},{"issue":"18","key":"2968_CR8","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.1073\/pnas.0602033103","volume":"103","author":"S Palmer","year":"2006","unstructured":"Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA. 2006;103(18):7094\u20139. https:\/\/doi.org\/10.1073\/pnas.0602033103.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2968_CR9","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","volume":"17","author":"B Brenner","year":"2003","unstructured":"Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. Aids. 2003;17(1):F1\u20135.","journal-title":"Aids"},{"issue":"7","key":"2968_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1086\/378281","volume":"188","author":"JM Whitcomb","year":"2003","unstructured":"Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188(7):992\u20131000. https:\/\/doi.org\/10.1086\/378281.","journal-title":"J Infect Dis"},{"key":"2968_CR11","doi-asserted-by":"publisher","unstructured":"Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). 1989;246(4934):1155\u20138. https:\/\/doi.org\/10.1126\/science.2479983","DOI":"10.1126\/science.2479983"},{"issue":"1","key":"2968_CR12","first-page":"56","volume":"17","author":"JM Llibre","year":"2015","unstructured":"Llibre JM, Pulido F, Garc\u00eda F, Garc\u00eda Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17(1):56\u201364.","journal-title":"AIDS Rev"},{"issue":"7","key":"2968_CR13","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.3390\/v7072790","volume":"7","author":"T Mespl\u00e8de","year":"2015","unstructured":"Mespl\u00e8de T, Wainberg MA. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses. 2015;7(7):3703\u201318.","journal-title":"Viruses"},{"issue":"3","key":"2968_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/s1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346\u201355. https:\/\/doi.org\/10.1016\/s1473-3099(17)30702-8.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2968_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/infdis\/jiv383","volume":"213","author":"A Derache","year":"2016","unstructured":"Derache A, Wallis CL, Vardhanabhuti S, Bartlett J, Kumarasamy N, Katzenstein D. Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection. J Infect Dis. 2016;213(2):250\u20136. https:\/\/doi.org\/10.1093\/infdis\/jiv383.","journal-title":"J Infect Dis"},{"issue":"6","key":"2968_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/aid.2018.0272","volume":"35","author":"S Karade","year":"2019","unstructured":"Karade S, Sen S, Sashindran VK. Absence of integrase strand transfer inhibitor associated resistance in antiretroviral therapy na\u00efve and experienced individuals from western India. AIDS Res Hum Retroviruses. 2019;35(6):567\u201371. https:\/\/doi.org\/10.1089\/aid.2018.0272.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9596","key":"2968_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"lancet"},{"issue":"4","key":"2968_CR18","first-page":"559","volume":"30","author":"AM Wensing","year":"2022","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, G\u00fcnthard HF, Paredes R, et al. 2022 update of the drug resistance mutations in HIV-1. Top antiviral Med. 2022;30(4):559\u201374.","journal-title":"Top antiviral Med"},{"issue":"2","key":"2968_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000331998","volume":"55","author":"MW Tang","year":"2012","unstructured":"Tang MW, Liu TF, Shafer RW. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012;55(2):98\u2013101. https:\/\/doi.org\/10.1159\/000331998.","journal-title":"Intervirology"},{"issue":"Supplement1","key":"2968_CR20","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1086\/505356","volume":"194","author":"W Shafer Robert","year":"2006","unstructured":"Shafer Robert W. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Supplement1):S51\u20138. https:\/\/doi.org\/10.1086\/505356.","journal-title":"J Infect Dis"},{"key":"2968_CR21","doi-asserted-by":"publisher","first-page":"100520","DOI":"10.1016\/j.ijmmb.2023.100520","volume":"47","author":"S Sivamalar","year":"2024","unstructured":"Sivamalar S, Gomathi S, Boobalan J, Balakrishnan P, Pradeep A, Devaraj CA, et al. Delayed identification of treatment failure causes high levels of acquired drug resistance and less future drug options among HIV-1-infected South Indians. Ind J Med Microbiol. 2024;47:100520.","journal-title":"Ind J Med Microbiol"},{"issue":"3","key":"2968_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/aid.2016.0070","volume":"33","author":"S Sivamalar","year":"2017","unstructured":"Sivamalar S, Dinesha TR, Gomathi S, Pradeep A, Boobalan J, Solomon SS, et al. Accumulation of HIV-1 drug resistance mutations after first-line immunological failure to evaluate the options of recycling NRTI drugs in second-line treatment: a study from South India. AIDS Res Hum Retroviruses. 2017;33(3):271\u20134.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"12","key":"2968_CR23","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1089\/aid.2016.0110","volume":"32","author":"TR Dinesha","year":"2016","unstructured":"Dinesha TR, Gomathi S, Boobalan J, Sivamalar S, Solomon SS, Pradeep A, et al. Genotypic HIV-1 drug resistance among patients failing tenofovir-based first-line HAART in South India. AIDS Res Hum Retroviruses. 2016;32(12):1234\u20136.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"46","key":"2968_CR24","doi-asserted-by":"publisher","first-page":"17355","DOI":"10.1073\/pnas.0607274103","volume":"103","author":"SY Rhee","year":"2006","unstructured":"Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA. 2006;103(46):17355\u201360. https:\/\/doi.org\/10.1073\/pnas.0607274103.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2968_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jiw219","volume":"214","author":"TS Boender","year":"2016","unstructured":"Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, et al. Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa. J Infect Dis. 2016;214(6):873\u201383.","journal-title":"J Infect Dis"},{"issue":"4","key":"2968_CR26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1128\/AAC.01228-07","volume":"52","author":"I Malet","year":"2008","unstructured":"Malet I, Delelis O, Valantin M-A, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52(4):1351\u20138.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02968-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02968-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02968-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:19Z","timestamp":1791061339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02968-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":26,"alternative-id":["2968"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02968-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"12 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest regarding this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required. All sequences are publicly available through LANL (\n                      \n                      ) and NCBI GenBank. No patient-identifiable information was accessed or analysed.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the authors used Claude Sonnet 4.6 in order to improve language of the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}]}}